The Controversies of Statin Therapy
- 15 August 2012
- journal article
- review article
- Published by Elsevier BV in Journal of the American College of Cardiology
- Vol. 60 (10), 875-881
- https://doi.org/10.1016/j.jacc.2012.07.007
Abstract
The debate whether statins, 3-hydroxymethyl-3-methylglutaryl coenzyme A reductase inhibitors, are safe to use has been raging since their introduction in 1987. Statins are generally well tolerated and are believed to have minimal adverse effects. However, individual, specific rare adverse events have been reported, such as elevations of liver enzymes, muscle aches, and very rarely, rhabdomyolysis. Discontinuation and/or reduction in the dose of the statin usually leads to resolution of these side effects. Recently, however, debate has focused on the possible negative long-term effects of statin treatment on cognitive decline, the incidence of cancer, and the development of diabetes mellitus. Recently, the U.S. Food and Drug Administration has expanded the warning for statins with a statement that statin use may lead to cognitive impairment. In this review, we discuss all levels of evidence, from case reports to large randomized controlled clinical trials, for the possible adverse effects of statins on cognitive decline, cancer, and diabetes. After careful consideration of all discussed scientific evidence, we conclude that there is no increased risk of cognitive decline or cancer with statin use. However, statin use is related to a small increased risk of type 2 diabetes mellitus. In view of the overwhelming benefit of statins in the reduction of cardiovascular events, we believe the small absolute risk for development of diabetes is outweighed by the cardiovascular benefits in patients for whom statin therapy is recommended. We, therefore, suggest that clinical practice for statin therapy should not be changed on the basis of the most recent Food and Drug Administration informational warnings.Keywords
Funding Information
- Astellas
- AstraZeneca
- Bayer
- Biotronik
- Boston Scientific
- Daiichi Sankyo
- Eli Lilly and Co.
- Genzyme
- Medtronic
- Merck-Schering-Plough
- Pfizer
- Orbus Neich
- Novartis
- Roche
- Servier
- Sanofi Aventis
- The Netherlands Heart Foundation
- Interuniversity Cardiology of the Netherlands
- European Community Framework KP7 Programme
- Ainylam
- Bristol-Myers Squibb
- Pfizer
- Accumetrics
- AstraZeneca
- Essentialis
- GlaxoSmithKline
- Merck
- Regeneron
- Sanofi
- Takeda
This publication has 68 references indexed in Scilit:
- Is Statin-Associated Cognitive Impairment Clinically Relevant? A Narrative Review and Clinical RecommendationsAnnals of Pharmacotherapy, 2012
- Adverse events associated with individual statin treatments for cardiovascular disease: an indirect comparison meta-analysisQJM: An International Journal of Medicine, 2011
- Observational Research, Randomised Trials, and Two Views of Medical SciencePLoS Medicine, 2008
- Life long changes in cognitive ability are associated with prescribed medications in old ageInternational Journal of Geriatric Psychiatry, 2004
- Statin‐Associated Memory Loss: Analysis of 60 Case Reports and Review of the LiteraturePharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2003
- The Impact of the Use of Statins on the Prevalence of Dementia and the Progression of Cognitive ImpairmentThe Journals of Gerontology: Series A, 2002
- Serum Lipoprotein Levels, Statin Use, and Cognitive Function in Older WomenArchives of Neurology, 2002
- Use of Lipid-Lowering Agents, Indication Bias, and the Risk of Dementia in Community-Dwelling Elderly PeopleArchives of Neurology, 2002
- Statins and the risk of dementiaThe Lancet, 2000
- Recent Trends in Acute Coronary Heart Disease — Mortality, Morbidity, Medical Care, and Risk FactorsNew England Journal of Medicine, 1996